This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Masui, H. Articles by Mendelsohn, J. Search for Related Content PubMed PubMed Citation Articles by Masui, H. Articles by Mendelsohn, J.

Mechanism of Antitumor Activity in Mice for Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Isotypes¹

Memorial Sloan-Kettering Cancer Center, New York, New York 10021

In previous studies of monoclonal antibodies (mAbs) against the receptor for epidermal growth factor (EGF) both 528 IgG2a and 225 IgG1 were shown to inhibit growth of A431 cell xenografts in athymic mice. The antitumor activities of the two mAbs were similar and, although they differ in their isotypes, they share many properties. The two mAbs bind to EGF receptors with identical affinities, compete with EGF for binding to EGF receptors, down regulate the receptors identically, block EGF-induced activation of tyrosine protein kinase activity to a comparable degree, and block EGF-induced changes in the proliferation of cultured cells. These similarities in physiological effects permit a direct comparison of the mechanisms of action mAbs of the IgG1 and IgG2a isotypes. We examined in vitro cytotoxicity against A431 cells, using 528 IgG2a and 225 IgG1 mAbs. 528 IgG2a, but not 225 IgG1, demonstrated partial complement-mediated cytotoxicity by the ⁵¹Cr release assay and by growth inhibition of cultured A431 cells. 528 IgG2a, but not 225 IgG1, was cytotoxic to A431 cells in the presence of activated peritoneal macrophages, as demonstrated by release of incorporated [³H]thymidine. Neither mAb showed any significant cytotoxicity to A431 cells in the presence of nonadherent spleen cells which contain K-cells. The results of in vitro cytotoxicity experiments suggested that the antitumor activity of 528 IgG2a, but not 225 IgG1, could be mediated by macrophages. This was verified by in vivo experiments in which s.c. tumor cell inocula containing activated macrophages showed enhancement of antitumor effects in animals treated i.p. twice weekly for 3 weeks with suboptimal doses of 528 IgG2a. This enhancement was not observed when 225 IgG1 was used with the same procedure. The results of these experiments suggest that immune mechanisms involving activated macrophages or complement could contribute to the antitumor activity of anti-EGF receptor mAb with the IgG2a isotype, but not with the IgG1 isotype. This observation confirms the findings of others who examined the antitumor activity of IgG2a mAbs in other model systems. IgG1 mAb 225, and possibly IgG2a mAb 528, may prevent growth of human tumor xenografts by altering the physiological functions of the EGF receptor rather than by immune mechanisms.

¹ This work was supported by NIH Grants CA-42060, CA-37641, and CA-23052.

² To whom requests for reprints should be addressed, at Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021.

³ Present address: Hiroshima University Dental School, Hiroshima, Japan.

Received 2/12/86. Revised 7/22/86. Accepted 7/28/86.

This article has been cited by other articles:

				T. G. Johns, R. M. Perera, S. C. Vernes, A. A. Vitali, D. X. Cao, W. K. Cavenee, A. M. Scott, and F. B. Furnari The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization Clin. Cancer Res., March 15, 2007; 13(6): 1911 - 1925. [Abstract] [Full Text] [PDF]

				V. P. Wittman, D. Woodburn, T. Nguyen, F. A. Neethling, S. Wright, and J. A. Weidanz Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death J. Immunol., September 15, 2006; 177(6): 4187 - 4195. [Abstract] [Full Text] [PDF]

				N. R. Schechter, R. E. Wendt III, D. J. Yang, A. Azhdarinia, W. D. Erwin, A. M. Stachowiak, L. D. Broemeling, E. E. Kim, J. D. Cox, D. A. Podoloff, et al. Radiation Dosimetry of 99mTc-Labeled C225 in Patients with Squamous Cell Carcinoma of the Head and Neck J. Nucl. Med., October 1, 2004; 45(10): 1683 - 1687. [Abstract] [Full Text] [PDF]

				W. K. Bleeker, J. J. Lammerts van Bueren, H. H. van Ojik, A. F. Gerritsen, M. Pluyter, M. Houtkamp, E. Halk, J. Goldstein, J. Schuurman, M. A. van Dijk, et al. Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy J. Immunol., October 1, 2004; 173(7): 4699 - 4707. [Abstract] [Full Text] [PDF]

				T. Karashima, P. Sweeney, J. W. Slaton, S. J. Kim, D. Kedar, J. I. Izawa, Z. Fan, C. Pettaway, D. J. Hicklin, T. Shuin, et al. Inhibition of Angiogenesis by the Antiepidermal Growth Factor Receptor Antibody ImClone C225 in Androgen-independent Prostate Cancer Growing Orthotopically in Nude Mice Clin. Cancer Res., May 1, 2002; 8(5): 1253 - 1264. [Abstract] [Full Text] [PDF]

				D. M. Shin, N. J. Donato, R. Perez-Soler, H. J. C. Shin, J. Y. Wu, P. Zhang, K. Lawhorn, F. R. Khuri, B. S. Glisson, J. Myers, et al. Epidermal Growth Factor Receptor-targeted Therapy with C225 and Cisplatin in Patients with Head and Neck Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1204 - 1213. [Abstract] [Full Text]

				V. A. Pollack, D. M. Savage, D. A. Baker, K. E. Tsaparikos, D. E. Sloan, J. D. Moyer, E. G. Barbacci, L. R. Pustilnik, T. A. Smolarek, J. A. Davis, et al. Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 739 - 748. [Abstract] [Full Text]

				X.-D. Yang, X.-C. Jia, J. R. F. Corvalan, P. Wang, C. G. Davis, and A. Jakobovits Eradication of Established Tumors by a Fully Human Monoclonal Antibody to the Epidermal Growth Factor Receptor without Concomitant hemotherapy Cancer Res., March 1, 1999; 59(6): 1236 - 1243. [Abstract] [Full Text] [PDF]

				D. Fry, A. Kraker, A McMichael, L. Ambroso, J. Nelson, W. Leopold, R. Connors, and A. Bridges A specific inhibitor of the epidermal growth factor receptor tyrosine kinase Science, August 19, 1994; 265(5175): 1093 - 1095. [Abstract] [PDF]

				D. C. Saffran, A. B. Raitano, R. S. Hubert, O. N. Witte, R. E. Reiter, and A. Jakobovits Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts PNAS, February 27, 2001; 98(5): 2658 - 2663. [Abstract] [Full Text] [PDF]